A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men
Open Access
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesionsEuropean Journal of Cancer, 2015
- A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in WomenNew England Journal of Medicine, 2015
- Large contribution of human papillomavirus in vaginal neoplastic lesions: A worldwide study in 597 samplesEuropean Journal of Cancer, 2014
- Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwideInternational Journal of Cancer, 2014
- Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulvaEuropean Journal of Cancer, 2013
- Potential impact of a nine-valent vaccine in human papillomavirus related cervical diseaseInfectious Agents and Cancer, 2012
- HPV Vaccine against Anal HPV Infection and Anal Intraepithelial NeoplasiaNew England Journal of Medicine, 2011
- Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in MalesNew England Journal of Medicine, 2011
- Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide studyThe Lancet Oncology, 2010
- Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 diseaseVaccine, 2006